Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014580 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL2902593 | 0.81 | ALDH1A1 (0.66) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL18585976 | 0.81 | ALDH1A1 (0.59) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL3160169 | 0.79 | KDM6B (0.63) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL2898616 | 0.79 | GAA (0.56) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL23900636 | 0.79 | ALDH1A1 (0.63) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL4772015 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL6706506 | 0.79 | GAA (0.63) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL2217764 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL4768247 | 0.79 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0871707-A4 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | PHYTERA INC (US) | 2000-10-25 | — | — | EP | claimed |
| EP-0871707-A1 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | PHYTERA, INC. (US) | 1998-10-21 | — | — | EP | claimed |
| WO-1997026873-A1 | ANTIMICROBIAL AURONE DERIVATIVES | PHYTERA, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1996036693-A9 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | — | 1997-01-23 | — | — | WO | claimed |
| WO-1996036693-A1 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | PHYTERA, INC. (US) | 1996-11-21 | — | — | WO | claimed |
| CN-114245796-B | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267576-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116867781-A | Imidazo [1,2-a ] pyridine derivatives as IRAK4 inhibitors and their use in the treatment of diseases | 渤健马萨诸塞州股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-114716961-B | Self-complementary quadruple hydrogen bond supermolecule hot melt adhesive and synthesis method thereof | 郑州大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| CN-114716961-A | Self-complementary quadruple hydrogen bond supramolecular hot melt adhesive and synthesis method thereof | 郑州大学 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022140425-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3990454-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Biogen MA Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114245796-A | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease | 比奥根MA公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2020263980-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-0871707-A4 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | PHYTERA INC (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-0871707-A1 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | PHYTERA, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1996036693-A9 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | — | 1997-01-23 | — | — | WO | disclosed |
| WO-1996036693-A1 | MANIPULATION OF PLANT CELL AND TISSUE CULTURES | PHYTERA, INC. (US) | 1996-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116922-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK1, IRAK2 | KDM4E 155/4885ALDH1A1 1401/4885L3MBTL1 1605/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | KDM4E 114/4885ALDH1A1 1138/4885L3MBTL1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.